Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Drug Toxicity: Risk factors
Connective Tissue Cell Types
Atherosclerosis III: Management
Therapeutic Drug Monitoring: Affecting Factors
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: May 3, 2026

Author Spotlight: Integrating Mechanical and Biological Analysis in Tendinopathy Research
Published on: March 1, 2024
Tahmeed Contractor1, Abhimanyu Beri, Joseph C Gardiner
11Division of Cardiology, Lehigh Valley Health Network, Allentown, PA; 2Department of Clinical Cardiac Electrophysiology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA; 3Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, MI; 4Center for Health Research, Geisinger Health System, Danville, PA; and 5Department of Medicine, Michigan State University, East Lansing, MI.
Statins, or 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors (HMG-CoA-Is), do not appear to increase the risk of tendon rupture. This large population study found no significant difference in tendon rupture rates between HMG-CoA-I users and nonusers.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: